Healthcare

This bill establishes a new process for the Department of Veterans Affairs (VA) to lease major medical facilities without requiring General Services Administration (GSA) approval. It creates a Veterans Leasing Fund to finance these leases and sets requirements for cost estimation, lease terms (maximum 20 years), and reporting to Congress. The bill mandates detailed cost estimates including construction, land, and material costs, with notifications to Congress if costs exceed approved estimates by more than 10%. It sets a one-year target for awarding leases and requires annual reports on procurement progress. The goal is to streamline the VA's process for building and leasing medical facilities for veterans.

HR 5385, the Health Providers Training Act, expands eligibility for existing health profession opportunity grants under the Social Security Act. It amends the law to include hospitals (as defined in Section 1861(e)) as eligible recipients alongside community-based organizations. This change allows hospitals to apply for federal grants aimed at training health professionals, directly affecting qualifying hospitals seeking funding for workforce development. The amendment takes effect on October 1, 2025.

HR 3375, the Fair Prescription Drug Prices for Americans Act, sets a cap on the U.S. list price for prescription drugs and biological products, limiting it to the average price charged in Canada, France, Germany, Italy, Japan, and the United Kingdom. Drug manufacturers must annually report U.S. and international list prices to the Health and Human Services Secretary, who calculates the average price for each drug. Manufacturers violating the price cap face civil penalties equal to 10 times the price difference per unit sold in the U.S. The bill directly affects drug manufacturers by restricting U.S. pricing and imposing financial penalties for noncompliance.

HR 6000, the Veterans’ Sentinel Act, requires the Department of Veterans Affairs (VA) to improve data collection and analysis of suicides and attempted suicides occurring on VA property. It mandates an annual evaluation of trends and prevention recommendations, establishes a working group to review root cause data (including Behavioral Health Autopsy Program findings), and standardizes data collection across VA facilities. The working group must develop unified reporting systems, modify incident forms to include on-campus suicide data, and coordinate with medical centers. The VA must submit annual briefings to congressional committees and a final report detailing the working group’s effectiveness and data management improvements. This bill directly affects VA facilities and veterans who experience suicide-related incidents on VA property.

HR 5946, the "Stamp Out Veterans Medical Debt Act," creates a special postage stamp sold by the U.S. Postal Service to raise funds for paying veterans' outstanding medical debt. The bill requires all revenue from stamp sales to be transferred directly to the Department of Veterans Affairs (VA), where it is used to reduce unresolved copayments and coinsurance bills for veterans who received care through VA facilities or the Community Care Program. The stamp must be available by Veterans Day each year and has no sales limits, allowing public contributions to directly offset veterans' medical debt. This bill directly affects veterans with unpaid medical bills and enables the public to support debt relief through a simple postage purchase.

HRES 898 is a non-binding resolution recognizing November 2025 as "National Family Caregivers Month" in the U.S. It directly acknowledges the work of approximately 63 million family caregivers who provide unpaid care worth an estimated $600 billion annually. The resolution encourages federal agencies, states, and the private sector to support existing efforts like the 2022 National Strategy to Support Family Caregivers, and urges policies such as tax credits, paid leave, respite care, and home-based services. It does not create new laws or funding but aims to raise awareness and advocate for caregiver support. This is a symbolic recognition measure, not a legislative change.

Medicare for All Act This bill establishes a national health insurance program that is administered by the Department of Health and Human Services (HHS). Among other requirements, the program must (1) cover all U.S. residents; (2) provide for automatic enrollment of individuals upon birth or residency in the United States; and (3) cover items and services that are medically necessary or appropriate to maintain health or to diagnose, treat, or rehabilitate a health condition, including hospital services, prescription drugs, mental health and substance abuse treatment, dental and vision services, long-term care, gender affirming care, and reproductive care, including contraception and abortions. The bill prohibits cost-sharing (e.g., deductibles, coinsurance, and copayments) and other charges for covered services. Additionally, private health insurers and employers may only offer coverage that is supplemental to, and not duplicative of, benefits provided under the program. Health insurance exchanges and specified federal health programs terminate upon program implementation. However, the program does not affect coverage provided through the Department of Veterans Affairs or the Indian Health Service. The bill also establishes a series of implementing provisions relating to (1) health care provider participation; (2) HHS administration; and (3) payments and costs, including the requirement that HHS negotiate prices for prescription drugs. Individuals who are age 18 or younger, age 55 or older, or already enrolled in Medicare may enroll in the program starting one year after enactment of this bill; other individuals may buy into the program at this time. The program must be fully implemented two years after enactment.

The Health Access Innovation Act of 2025 establishes a federal grant program to fund community-based organizations in medically underserved areas. These organizations, which must address health disparities and serve communities disproportionately affected by them, will use funds to expand culturally and linguistically appropriate care, support community health workers (like promotores de salud), and address social barriers to health. The program authorizes $50 million in 2026, increasing to $70 million by 2029, with 5% of funds allowed for administrative costs. Priority is given to groups that operated health programs during recent public health emergencies.

The Hospice Recertification Flexibility Act extends the ability for hospice providers to use telehealth for patient recertifications (verifying ongoing eligibility for hospice care) until December 31, 2027, instead of ending in March 2025. It specifies that telehealth recertifications will not apply in certain cases starting January 1, 2026, such as when patients are in areas with a hospice enrollment moratorium or when providers are under enhanced oversight. The bill also requires hospice claims for telehealth recertifications on or after January 1, 2026, to include a specific modifier or code indicating the telehealth encounter. This change directly affects hospice providers and their patients by modifying how remote eligibility checks are processed under Medicare.

HR 843, the Prompt Approval of Safe Generic Drugs Act, modifies FDA drug approval rules to prevent delays in approving generic drugs solely because safety information (like warnings or dosing instructions) is omitted from labeling due to existing patent or market exclusivity protections. It ensures that generic drug applications submitted under specific pathways (like 505(b)(2) or 505(j)) cannot be rejected or deemed misbranded for missing such safety details if the omission stems from protected exclusivity. The bill requires the FDA to mandate inclusion of necessary safety statements in labeling for these approved drugs while preserving existing patent and exclusivity rules. This directly affects generic drug manufacturers and the FDA’s review process, streamlining approvals without altering current exclusivity periods.